Friday, 29 March 2024


Mesoblast licensee seeks expanded indication for stem cell product in Japan

24 October 2018 | News

Mesoblast will be eligible to receive royalties on TEMCELL sales for EB. It is currently approved in Japan for the treatment of acute graft-versus-host disease.

Singapore –  Mesoblast announces that Japanese licensee JCR Pharmaceuticals Co. Ltd. plans to seek a new indication for its mesenchymal stem cell product, branded as TEMCELL HS Inj in Japan, for the treatment of wound healing in patients with epidermolysis bullosa (EB), a rare skin-blistering disorder.

Mesoblast will be eligible to receive royalties on TEMCELL sales for EB. It is currently approved in Japan for the treatment of acute graft-versus-host disease.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account